Clinical outcomes of bivalirudin for ischemic heart disease
about
Debate: Should the elderly receive thrombolytic therapy or primary angioplasty?Bivalirudin: a direct thrombin inhibitor for percutaneous transluminal coronary angioplastyEnoxaparin injection for the treatment of high-risk patients with non-ST elevation acute coronary syndromeTreatment of heparin-induced thrombocytopenia.Drug insight: bleeding after percutaneous coronary intervention-risks, measures and impact of anticoagulant treatment options.Argatroban, a direct thrombin inhibitor for heparin-induced thrombocytopaenia: present and future perspectives.Heparin in interventional radiology: a therapy in evolutionRegular review: treatment possibilities for unstable angina.Bivalirudin for percutaneous coronary intervention and in acute coronary syndromes.Risk stratification in non-ST segment elevation acute coronary syndromes with special focus on recent guidelines.Novel uses for current and future direct thrombin inhibitors: focus on ximelagatran and bivalirudin.Anticoagulant drugs: an update.New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarinThrombin inhibitors and cardiopulmonary bypass.The status of new anticoagulants.Efficacy and safety of bivalirudin versus heparins in reduction of cardiac outcomes in acute coronary syndrome and percutaneous coronary interventions.New anticoagulant strategies in ST elevation myocardial infarction: trials and clinical implicationsAntithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding.
P2860
Q24792815-F7074EAC-E4A7-48C1-9225-B49C9180EE0BQ28193596-F82E2DB3-3249-41F0-B7F1-E122F859C4CEQ28213718-498CDE47-D0BF-4727-B96C-D5C2C440AE3CQ31042575-BE6F718B-66B1-42B5-AB7B-1936D9B97F10Q33369119-E9F3EDAC-5622-4BBF-A67A-001839001E71Q33369690-F0AABCA0-0614-43E3-8D82-65DA676C2115Q33394179-5C54BEE1-A2E5-48A8-85FF-715D557DD85CQ33802938-0DE47C2F-44B5-44D5-B78F-8D3122FB82C7Q34336816-7B453947-0D33-4DC2-9ECE-0F4112510071Q34445660-5426E148-9AA9-4AED-A3B6-0B92C3372680Q35779232-00A3D395-64C1-4621-BFF6-845B74521B51Q35821887-F75404B6-AF45-4276-B941-210A5406B225Q36042279-1AE4CE15-4828-4CB2-99F1-72EC38A4B0F3Q36459338-7866E9C7-9F49-4206-A5DC-0E9AAC07A094Q36520745-2DBCF61C-87F3-4EAB-B6B7-F969A88D2C88Q37048950-9AEF3E14-C5D8-4C24-8810-4A385B938EE6Q37193906-5C261885-DB08-467B-9683-1EC51F71B5E7Q37670997-0E0DDE13-ADE0-427E-8700-0CDCCFFAAFC6
P2860
Clinical outcomes of bivalirudin for ischemic heart disease
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
name
Clinical outcomes of bivalirudin for ischemic heart disease
@ast
Clinical outcomes of bivalirudin for ischemic heart disease
@en
Clinical outcomes of bivalirudin for ischemic heart disease
@nl
type
label
Clinical outcomes of bivalirudin for ischemic heart disease
@ast
Clinical outcomes of bivalirudin for ischemic heart disease
@en
Clinical outcomes of bivalirudin for ischemic heart disease
@nl
prefLabel
Clinical outcomes of bivalirudin for ischemic heart disease
@ast
Clinical outcomes of bivalirudin for ischemic heart disease
@en
Clinical outcomes of bivalirudin for ischemic heart disease
@nl
P2093
P1433
P1476
Clinical outcomes of bivalirudin for ischemic heart disease
@en
P2093
P304
P356
10.1161/01.CIR.100.20.2049
P407
P577
1999-11-16T00:00:00Z